Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Daily Moderate Exercise Can Improve Outcomes in Patients with Metastatic Colorectal Cancer

TON - March 2017, Vol 10, No 2 - Colorectal Cancer
Wayne Kuznar

San Francisco, CA—Daily moderate physical activity can improve outcomes in patients with metastatic colorectal cancer (CRC).

In a large clinical trial, patients who reported engaging in physical activity equivalent to ≥30 minutes of moderate exercise daily at the time of chemotherapy initiation had a 19% reduction in mortality, and a 16% reduction in disease progression, said lead investigator Brendan Guercio, MD, resident physician, Brigham and Women’s Hospital, Boston, MA, at the 2017 Gastrointestinal Cancers Symposium.

The data are the first evidence of a link between exercise and outcomes in patients with CRC and distant metastases. Previous studies have consistently shown a link between regular exercise and improved outcomes in patients with early-stage CRC without distant metastases.

The findings suggest that “even light activities that many metastatic cancer patients might be able to participate in could be associated with improved outcome,” said Dr Guercio.

Patients who are physically active tend to tolerate chemotherapy better, he noted, adding that patients with CRC often seek more information about lifestyle changes that may improve their outcomes.

The analysis included 1231 patients who were enrolled in the phase 3 CALGB 80405 trial of chemotherapy for metastatic CRC. At the time of chemotherapy initiation, patients completed questionnaires that included self-reports on 9 leisure-time physical activities and their average walking pace. The total metabolic equivalent task-hours per week were determined by the responses.

Compared with the least physically active patients (ie, those who engaged in less than 3 metabolic equivalent task-hours per week of activity), those who engaged in ≥18 metabolic equivalent task-hours per week, equivalent to ≥30 minutes each day of moderate physical activity (ie, walking, cleaning, or gardening), had an adjusted hazard ratio for overall survival of 0.81 (P = .03) and for progression-free survival of 0.84 (P = .03).

In an exploratory analysis, “we also found that individuals walking 4 or more hours per week had a greater than 20% improvement in overall survival. Walking pace, on the other hand, was not associated with the outcomes we assessed in this study [progression-free survival and overall survival],” said Dr Guercio.

In addition, ≥5 hours per week of nonvigorous activity (eg, walking or yoga) was associated with a 25% improvement in overall survival.

When adjusting for confounders, such as comorbidities, weight change over the previous 6 months, performance status, body mass index, type of chemotherapy received, tumor KRAS status, sex, and age, the association between moderate activity and outcomes remained significant, said Dr Guercio.

Randomized controlled trials and more prospective clinical studies are needed to confirm these associations in metastatic CRC, he added. An ongoing randomized clinical trial is comparing survival in patients who exercise during treatment and those who do not.

“Physical activity can be difficult for patients with advanced colorectal cancer, but this study shows that even a small amount of exercise may make a big difference. It’s important to help our patients find ways to incorporate moderate exercise into their daily lives—regardless of the stage of their disease,” added American Society of Clinical Oncology expert Nancy Baxter, MD, PhD, Chief, Department of General Surgery, St. Michael’s Hospital, Toronto.

Related Items
Assessment of Opioid Misuse and Abuse Should Be Part of Cancer Pain Management
Wayne Kuznar
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in NCCN 2019 Conference, Pain Management
First Positive Showing for Mesothelin-Directed CAR T-Cell Therapy in Solid Tumors
Wayne Kuznar
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Immunotherapy
Luspatercept, First-in-Class Erythroid Maturation Agent, Reduces Transfusions in Patients with Low-Risk MDS
Wayne Kuznar
TON - April 2019, Vol 12, No 2 published on April 22, 2019
Nivolumab-Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer
Wayne Kuznar
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Colorectal Cancer
First-Line Ibrutinib Improves Outcomes Compared with Current Standard of Care in Older Patients with Chronic Lymphocytic Leukemia
Wayne Kuznar
TON - February 2019, Vol 12, No 1 published on March 1, 2019 in Leukemia
Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
TON - November 2018, Vol 11, No 5 published on November 28, 2018 in Immunotherapy
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
Wayne Kuznar
TON - September 2018, Vol 11, No 4 published on September 19, 2018 in Lynch Syndrome
Nivolumab Shows Durable Activity in Subgroups of Patients with Metastatic CRC
Charles Bankhead
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Colorectal Cancer
Regorafenib Dose-Escalation Strategy Potentially a New Standard in Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Colorectal Cancer
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Immunotherapy
Last modified: March 14, 2017